[1]黄岩,吴雪卿.中药单体调控MAPKs信号通路治疗三阴性乳腺癌新辅助化疗后骨髓抑制研究进展[J].西部中医药,2026,39(07):153-157.[doi:10.12174/j.issn.2096-9600.2026.07.29]
　HUANG Yan,WU Xueqing.Research Progress on TCM Monomers Regulating the MAPKs Signaling Pathway in the Treatment of Bone Marrow Suppression Induced by Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2026,39(07):153-157.[doi:10.12174/j.issn.2096-9600.2026.07.29]
点击复制

中药单体调控MAPKs信号通路治疗三阴性乳腺癌新辅助化疗后骨髓抑制研究进展()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年07期
页码:
153-157
栏目:
研究进展
出版日期:
2026-07-12

文章信息/Info

Title:
Research Progress on TCM Monomers Regulating the MAPKs Signaling Pathway in the Treatment of Bone Marrow Suppression Induced by Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
作者:
黄岩, 吴雪卿
上海中医药大学附属曙光医院，上海 201203
Author(s):
HUANG Yan, WU Xueqing
Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China
关键词:
三阴性乳腺癌; 新辅助化疗; 骨髓抑制; 有丝分裂原活化蛋白激酶信号通路; 综述
Keywords:
triple-negative breast cancer; neoadjuvant chemotherapy; bone marrow suppression; MAPKs; literature review
分类号:
R285
DOI:
10.12174/j.issn.2096-9600.2026.07.29
文献标志码:
A
摘要:
系统梳理丝裂原活化蛋白激酶（mitogen-activated protein kinases，MAPKs）信号通路的组成与调控机制，阐析该通路在三阴性乳腺癌（triple-negative breast cancer，TNBC）新辅助化疗后骨髓抑制发生发展中的作用；基于MAPKs信号通路，分类归纳多酚类、黄酮类、萜类、皂苷类、多糖类、有机酸、生物碱等中药单体干预TNBC的相关研究进展。中药单体可通过调控细胞外信号调节激酶（extracellular signal-regulated kinase，ERK）、c-Jun氨基末端激酶（c-Jun N-terminal kinase，JNK）、p38丝裂原活化蛋白激酶（p38 mitogen-activated protein kinase，p38 MAPK）等通路分支，作用于RAF激酶（RAF kinase，RAF）、MAPK/ERK 激酶（MAPK/ERK kinase，MEK）、核因子κB（nuclear factor kappa-B，NF-κB）、激活蛋白1（activator protein 1，AP-1）、B细胞淋巴瘤2（B-cell lymphoma 2，Bcl-2）等上下游关键靶点，发挥抑制细胞增殖、诱导细胞凋亡、抗炎、抗氧化等核心药理效应。目前该领域研究多停留于体外细胞实验与动物实验阶段，缺乏大样本临床试验佐证；同时，中药单体对不同TNBC亚型的干预疗效差异及精准作用机制仍有待深入挖掘。现综述相关研究现状，旨在为TNBC新辅助化疗后骨髓抑制的临床防治提供安全有效的中医药干预思路，亦为后续基础机制研究与临床转化应用提供理论参考。
Abstract:
This review systematically summarizes the composition and regulatory mechanisms of the mitogen-activated protein kinases (MAPKs) signaling pathway, and clarifies its role in the occurrence and development of bone marrow suppression after neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). Based on the MAPKs signaling pathway, the paper systematically summarizes and categorizes the research progress of various TCM monomers, including polyphenols, flavonoids, terpenoids, saponins, polysac-charides, organic acids, and alkaloids, in intervening in TNBC. These TCM monomers exert their effects by regulating distinct branches of the MAPK signaling pathway, including the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK) pathways. They act on key upstream and downstream targets, such as RAF kinase (RAF), MAPK/ERK kinase (MEK), nuclear factor kappa-B (NF-κB), activator protein 1 (AP-1), and B-cell lymphoma 2 (Bcl-2), thereby exerting core pharmacological effects, including inhibition of cell proliferation, induction of apoptosis, anti-inflammatory activity, and antioxidant effects. Current research in this field is mostly confined to in vitro cell experiments and animal studies, lacking validation from large-scale clinical trials. Meanwhile, the differential therapeutic effects of TCM monomers on distinct subtypes of TNBC and their precise mechanisms of action remain to be further explored. This review summarizes the current state of related research, aiming to provide safe and effective TCM intervention strategies for the clinical prevention and treatment of bone marrow suppression following neoadjuvant chemotherapy for TNBC, as well as to offer a theoretical reference for subsequent basic mechanism research and clinical translational application.

相似文献/References:

[1]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[2]曲波,王海琳△,吴红彦,等.参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析[J].西部中医药,2017,30(08):1.
　QU Bo,WANG Hailin,WU Hongyan,et al.An Analysis of Clinical Effects of ShenQi Tumor-inhibiting Prescriptions Jointed with Neoadjuvant Chemotherapy in Treating Cervical Carcinoma at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2017,30(07):1.
[3]陈锡康,田华琴△.三阴性乳腺癌的治疗现状及进展[J].西部中医药,2018,31(11):135.
　CHEN Xikang,TIAN Huaqin.Therapeutic Status and Progress of Triple Negative Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2018,31(07):135.
[4]印海娟,郑杰,董涛,等.复方苦参注射液联合新辅助化疗对宫颈癌患者CA125、CA199、CEA的影响[J].西部中医药,2021,34(04):105.[doi:10.12174/j.issn.2096-9600.2021.04.26]
　YIN Haijuan,ZHENG Jie,DONG Tao,et al.Effects of Compound Kushen Injection Combined with Neoadjuvant Chemotherapy on CA125, CA199 and CEA in Patients with Cervical Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(07):105.[doi:10.12174/j.issn.2096-9600.2021.04.26]
[5]张佳慧,于明薇,王笑民,等.三阴性乳腺癌中西医治疗研究进展[J].西部中医药,2024,37(04):91.[doi:10.12174/j.issn.2096-9600.2024.04.18]
　ZHANG Jiahui,YU Mingwei,WANG Xiaomin,et al.Progress of Research on Chinese and Western Medicine Treatment of Triple-negative Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(07):91.[doi:10.12174/j.issn.2096-9600.2024.04.18]

备注/Memo

备注/Memo:
上海市卫生健康委员会科研课题计划（202040254）。黄岩（1998—），女，硕士学位，医师。研究方向：中西医结合治疗乳腺疾病。
更新日期/Last Update: 2026-07-15